May. 12 at 1:00 PM
$FLGT Surprised this hasn't benefitted more from rising risk over #huntavirus
$MRNA $NVAX large labs,
$FLGT was likely the single largest beneficiary of Covid 19 testing during the pandemic due to efficient test development and rapid turnaround. During that period
$FLGT amassed over
$1B in cash (
$30+ per share) and historical institutional relationships in CA plus new ones in TX and the Southeast since expanding lab capacity in tact. Meanwhile, the company trades at a 1/3 discount to its
$23 per share in cash despite
$350M in diagnostics revenue and a pharma business with rapidly nearing catalysts. Minimal cash burn and company has bought back 10% of outstanding stock YTD... and still buying.
